Predict your next investment

Corporation
RETAIL (NON-INTERNET/MOBILE) | Pharmacies
walgreens.com

See what CB Insights has to offer

Investments

12

Portfolio Exits

8

Partners & Customers

10

Service Providers

1

About Walgreens

Walgreens is a drugstore chain that provides multi-channel access to consumer goods and services and trusted, pharmacy, health and wellness services. Walgreens scope of pharmacy services includes retail, specialty, infusion, medical facility and mail service, along with respiratory services.

Walgreens Headquarter Location

200 Wilmot Road

Deerfield, Illinois, 60015,

United States

800-925-4733

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Walgreens

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Walgreens in 5 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

H

HLTH

92 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

P

Pharma Supply Chain

1,277 items

P

Pharma Supply Chain in Healthcare Tech Market Map

19 items

H

Health Monitoring & Diagnostics

203 items

At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem

Latest Walgreens News

Elizabeth Holmes: Lessons Learnt from the Rise and Fall of Theranos

Oct 17, 2021

Published A conflict exists between big tech and health care as highlighted by Theranos a lab testing clinic that Elizabeth Holmes founded at the age of 19. Enthusiastic investors move at a rapid speed when they spot a promising new venture and as a result dollars roll in and the hype beings to build. Theranos was said to develop a revolutionary lab test that could screen a variety of conditions using a single drop of blood. Indeed, this was a cost-efficient solution – the characteristic of big tech- so investors loved what the charismatic Holmes presented. Actually, this young founder fashioned herself after Steve Jobs, who is an Apple visionary. Based on those claims, Theranos hit a valuation of $9 billion but failed to transform the health care years later. As a result, a potential 20-year prison term awaits its founder which is a severe type of punishment to have been given to a healthcare company in recent years. The article will review the history and lessons learnt from the rise and fall of Theranos. The History of $9 Billion Blood-Testing Startup Elizabeth Holmes started Real-Time Cures which was later renamed Theranos in 2003 at the age of 19 and after dropping out of Stanford University. Actually, this young entrepreneur was inspired by her grandfather’s medical career as well as her summer internship at Singapore’s Genome Institute in 2003. Indeed after this internship, Holmes came up with an arm patch that was able to diagnose and treat medical conditions and wrote a patent application for it. In 2004 Shaunak Roy joined Theranos as its first employee and Channing Robertson joined the board as an adviser. Further, Holmes leveraged family connections to raise initial funding of nearly $6 million by the end of 2004. The first investors were Time Draper and Victor Palmieri. In 2005, a cartridge-and-reader system was the initial design of a Theranos device that relied on microfluidics and biochemistry. The Theranos 1.0 and the technology was set to be licensed to pharmaceutical firms to aid them in catching drug reactions during clinical trials. In 2006, the management fired Henry Mosley who served as the chief financial officer for questioning the reliability of Theranos technology and its honesty. In 2007, the premature Theranos 1.0 was used in a patient study in Tennessee and the company also announced its plan to sue 3 of its former employees for using its intellectual property. Later in September of the same year, a new prototype named the Edison was developed. The modification of Fisnar’s glue-dispensing robot was done by Apples’ designers that Holmes had poached and placed them in charge of architecting Edison’s overall feel and look. In 2009, Sunny Balwani joined Theranos with a background in business and software engineering. In 2010 both Holmes and Balwani presented a business proposition to Walgreens to run health clinics as well as pursued a partnership with Safeway. Part of the partnership was to create a new device with the capability of performing several classes of blood tests and therefore, in 2011 the Minilab was created. In 2012 Theranos signed a deal with Walgreens to launch devices in-store but missed agreed-upon milestones. At the same time, Theranos managed Safeway employee health clinic’s blood testing as a beta run. However, there are continuous differences and discrepancies between the values that Theranos gave. However, the CEO brushed off the chief medical officer’s concerns and later retired the following year. In the same year, Lieutenant Colonel David Shoemaker questioned Theranos regulatory strategy when Holmes approached him seeking an opportunity to deploy the device in the military. Later, a surprise inspection was carried out by the Center for Medicaid and Medicare Services (CMS) but Balwani confirmed to the officials that the device was still in the development stage. James Mattis who was a board member of Theranos managed to convince Colonel Shoemaker and a more limited experiment was allowed. In May 2013, Ian Gibbons, a former Theranos’ scientist introduced to Holmes by Channing Robertson committed suicide. He had joined the company in 2005 and was named the chief scientist. Also, a 4s model with a new website was launched in September 2013 although many Theranos’ scientists opposed this move because the technology was still being developed. In February 2014, Partner Fund bought 5.6 million Theranos’ shares at $17 a share as the company was valued at $9 billion while Elizabeth Holmes net worth stood at $5 billion. As a result, both Holmes and Theranos graced the cover of Fortune magazine and gained media attention. During her media briefings, Holmes reported that Theranos offered over 200 tests and was working towards pushing it to 1,000. However, in 2015 John Carreyrou, a Wall Street investigative reporter got a tip about this company’s unethical and harmful practices and contacted its former lab director on February 26. During this period, Theranos was operating at a limited capacity and generating unreliable patients’ results FDA gave Theranos its first approval in July 2015 yet scientists were concerned about its technology. However, Carreyrou was continuing with his investigation and published his first story about Theranos shortly before Holmes attending a conference. The story revealed how Theranos was struggling with its blood-testing technology but Holmes used the coming weeks to defend her company. With time facts about Theranos lab began coming out such as the FDA’s visit and report that indicated the company was shipping what it termed as an “uncleared medical device.” By November, both partnerships with Safeway and their relationship with Walgreens had fallen through. In January 2016, CMs cited concerns about Holmes’ labs and SEC began conducting its investigations. Sunny Balwani who served as the company president resigned leaving Holmes as the single top executive. Theranos closed all its Wellness Centres in Arizona and California when its partnership with Walgreens officially came to an end in June 2016. Also, in July Holmes was banned from the lab-testing industry for 2 years by CMS. As part of the settlement, she paid $30,000 to the regulatory body later in 2017 and Theranos accepted not to own or operate any clinical lab for the next two years. Theranos began pivoting on its new sample processor dubbed the minilab, shut down all its clinical labs and sent home around 340 employees. However, Theranos began facing lawsuits from its partners, investors and patients. As a result, the company began refunding all patients that took tests in its clinic in Arizona, continued to lay off the remaining even as the board members began departing. By the close of 2017, Theranos made a deal with Fortress Investment Group where it obtained a secured debt financing of $100 million to help it get through 2018. This transaction was pegged on certain development milestones that Theranos had hit such as working to get FDA to approve the Zika Virus. In March 2018, the Securities and Exchange Commission (SEC) charged Theranos, Holmes and Balwani with massive fraud. However, this was settled and Holmes was fined and barred from serving as an officer or director in any publicly-traded company for the next 10 years. Still, Theranos and Holmes are being investigated and Zika test development experienced some setbacks which might cause them to default the agreement it has with Fortress. By June 2018, the Department of Justice had charged Holmes with 9 nine counts of wire fraud and she stepped down as Theranos CEO. In September 2018, the company wrote to its shareholders telling them of its intention to formally dissolve and give Fortress its company patents and pay its creditors with the remaining funds. Lessons Learnt from Theranos’ Rise and Fall Avoid too much Funding at the Early Startup Stage Generally, venture capitalists and angel investors target both young and serial entrepreneurs with promising business ideas. As a result, a founder with an innovative idea may get tempted by the hype, constant inflow of investments as well as spiking valuation. While startups need cash to grow excess cash and attention from investors can undermine its founders’ focus. Still, investors hope to monetize as quickly as possible and this can put a lot of pressure on the founders and the team. It’s the pressure from impatient investors that forced Theranos and its team to run as fast as it could thus pushing it on a slippery slope and on to its ruin. They were probably not given enough time to mature the business model and perfect its technology. Otherwise had Theranos delivered a diagnostic test as promised, this would have achieved significant economies of scale. The goal was to use a single pinprick of blood to get a wide range of results. This provides a big lesson to investors, entrepreneurs and managers that they should avoid exposing startups to excessive funding and huge expectations on early-stage startups. Make Data-Driven Decisions Initially, the management presented itself as the transformative agent of healthcare but it didn’t have any clinical data to back its technology. As a result, Holmes and her team made erratic decisions that were not backed by any data hence the premature release of its testing devices. This strategic error has led to a lot of sanctions and hefty fines. On the other hand, maybe Theranos failed to make its data available to the public or use it because that could have undermined its astronomical valuation. Still, its investors would not have allowed it but the right course was to use and share its not-up-to standard data. Such transparency would have encouraged trust among its investors, partners, creditors, regulators and patients. Avoid Scaling Unproven Business Models Theranos had an aggressive go-to-market strategy. First, it shouldn’t have partnered with Safeway and Walgreens because this increased the potential value of premature technology. Further, this exposed the startup to a new set of performance targets that the young team was not ready to handle. A lesson to startups is that they should first demonstrate their business models viability before making so many promises too early. Therefore, entrepreneurs need to prove that their business models prior to making major decisions towards growth such as expansion, and acquisition. Innovation Always Improve so Manage Investors’ Expectations It’s not possible to nail everything in the first trial and therefore innovators should manage public expectations appropriately regarding what the new technology can and cannot do. Theranos and Holmes failed to manage investors, media and partners’ unrealistic expectations. Actually, the public would not have judged it harshly had it been less bold in its claims. The company would be given a chance to improve its technology and rectify any know errors. Further, Holmes’ invention was regarded by Ian Gibbons, the chief scientist as more of an idea than reality but he tried everything possible and exhausted every option because he was bound by the scientific method. Holmes on the other hand used her funds to hire communications specialists, salespersons and marketers. Sadly, the downfall of Theranos might make it hard for female founders. Some of Theranos high-profile investors comprise Oracle founder Larry Ellison, Rupert Murdoch, members of the Walton family and Betsy DeVos, the former US Secretary of Education. Conclusion Theranos is not the first startup to make mistakes in its early growth phase. However companies that successfully developed sustainable business models sourced funding after hitting specific milestones, made data-driven decisions, didn’t scale an unproven business model too soon and founders managed their stakeholders’ expectations. A startup’s cumulative outcomes of decisions made determine whether it will succeed or fail. Lessons picked from Elizabeth Holmes as well as the rise and fall of Theranos can help future innovative companies escape similar outcomes and live up to their potential.

Walgreens Investments

12 Investments

Walgreens has made 12 investments. Their latest investment was in Vim as part of their Series B - II on May 5, 2021.

CBI Logo

Walgreens Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/5/2021

Series B - II

Vim

$36M

Yes

1

7/31/2019

Private Equity

Shields Health Solutions

Yes

2

10/4/2018

Corporate Minority

Birchbox

Yes

2

1/29/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/5/2021

7/31/2019

10/4/2018

1/29/2018

7/15/2015

Round

Series B - II

Private Equity

Corporate Minority

Series C

Series B

Company

Vim

Shields Health Solutions

Birchbox

Subscribe to see more

Subscribe to see more

Amount

$36M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

2

10

10

Walgreens Portfolio Exits

8 Portfolio Exits

Walgreens has 8 portfolio exits. Their latest portfolio exit was Shields Health Solutions on September 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/21/2021

Corporate Majority

$991

3

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/21/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Corporate Majority

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Walgreens Acquisitions

11 Acquisitions

Walgreens acquired 11 companies. Their latest acquisition was Liz Earle on July 10, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/10/2015

Acquired

$991

Acquired - II

1

11/8/2013

Acquired

2

9/19/2012

$991

Acquired

2/6/2012

Management Buyout

Subscribe to see more

$99M

Subscribe to see more

10

6/7/2011

Acquired

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

7/10/2015

11/8/2013

9/19/2012

2/6/2012

6/7/2011

Investment Stage

Acquired

Management Buyout

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$99M

$99M

Note

Acquired - II

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

2

10

10

Walgreens Partners & Customers

10 Partners and customers

Walgreens has 10 strategic partners and customers. Walgreens recently partnered with Northwell Health on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/16/2021

Partner

Northwell Health

United States

Northwell Health enters partnership with Walgreens

`` We are very excited to partner with Walgreens to improve health , improve care and reduce costs through collaborative and innovative opportunities , '' said Mark Solazzo , president of strategic initiatives and chief operating officer for Northwell Health in a press release .

4

9/2/2021

Vendor

InComm

United States

Walgreens Launches Scarlet to Promote Financial Wellness for Customers and Patients

The latest evolution in the 12-year partnership between Walgreens and InComm was announced back in the spring , and was heralded as part of the drugstore chain 's `` alternative profit strategy '' and a `` broader initiative '' to offer a wider range of services to its customers .

1

8/17/2021

Partner

Synchrony

United States

Walgreens launches credit card program in partnership with Synchrony

And it could help Synchrony accelerate its pandemic recovery while offsetting growth challenges tied to the loss of several major partners , including Walmart and Gap .

1

7/23/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/8/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/16/2021

9/2/2021

8/17/2021

7/23/2021

7/8/2021

Type

Partner

Vendor

Partner

Partner

Partner

Business Partner

Northwell Health

InComm

Synchrony

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Northwell Health enters partnership with Walgreens

`` We are very excited to partner with Walgreens to improve health , improve care and reduce costs through collaborative and innovative opportunities , '' said Mark Solazzo , president of strategic initiatives and chief operating officer for Northwell Health in a press release .

Walgreens Launches Scarlet to Promote Financial Wellness for Customers and Patients

The latest evolution in the 12-year partnership between Walgreens and InComm was announced back in the spring , and was heralded as part of the drugstore chain 's `` alternative profit strategy '' and a `` broader initiative '' to offer a wider range of services to its customers .

Walgreens launches credit card program in partnership with Synchrony

And it could help Synchrony accelerate its pandemic recovery while offsetting growth challenges tied to the loss of several major partners , including Walmart and Gap .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

1

1

10

10

Walgreens Service Providers

1 Service Provider

Walgreens has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Walgreens Team

17 Team Members

Walgreens has 17 team members, including current Chief Financial Officer, Wade Miquelon.

Name

Work History

Title

Status

Wade Miquelon

Chief Financial Officer

Current

Abhi Dhar

Chief Technology Officer

Current

Kevin Ban

Chief Medical Officer

Current

Meen Kang

Senior Director

Current

Richard Ashworth

President

Former

Name

Wade Miquelon

Abhi Dhar

Kevin Ban

Meen Kang

Richard Ashworth

Work History

Title

Chief Financial Officer

Chief Technology Officer

Chief Medical Officer

Senior Director

President

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.